Kinetics and persistence of cellular and humoral immune responses to SARS‐CoV‐2 vaccine in healthcare workers with or without prior COVID‐19
Open Access
- 18 January 2022
- journal article
- research article
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 26 (4) , 1293-1305
Abstract
SARS‐CoV‐2 vaccines are highly efficient against severe forms of the disease, hospitalization and death. Nevertheless, insufficient protection against several circulating viral variants might suggest waning immunity and the need for an additional vaccine dose. We conducted a longitudinal study on the kinetics and persistence of immune responses in healthcare workers vaccinated with two doses of BNT162b2 mRNA vaccine with or without prior SARS‐CoV‐2 infection. No new infections were diagnosed during follow‐up. At 6 months, post‐vaccination or post‐infection, despite a downward trend in the level of anti‐S IgG antibodies, the neutralizing activity does not decrease significantly, remaining higher than 75% (85.14% for subjects with natural infection, 88.82% for vaccinated after prior infection and 78.37% for vaccinated only). In a live‐virus neutralization assay, the highest neutralization titres were present at baseline and at 6 months follow‐up in persons vaccinated after prior infection. Anti‐S IgA levels showed a significant descending trend in vaccinated subjects (p < 0.05) after 14 weeks. Cellular immune responses are present even in vaccinated participants with declining antibody levels (index ratio 1.1–3) or low neutralizing activity (30%–40%) at 6 months, although with lower T‐cell stimulation index (p = 0.046) and IFN‐γ secretion (p = 0.0007) compared to those with preserved humoral responses.Keywords
Funding Information
- Horizon 2020 Framework Programme (H2020‐SC1‐PHE‐CORONAVIRUS‐2020‐2‐RTD / no. 101016233)
This publication has 40 references indexed in Scilit:
- Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care WorkersNew England Journal of Medicine, 2021
- A whole blood test to measure SARS-CoV-2-specific response in COVID-19 patientsClinical Microbiology and Infection, 2021
- PD-1-Expressing SARS-CoV-2-Specific CD8+ T Cells Are Not Exhausted, but Functional in Patients with COVID-19Immunity, 2021
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UKThe Lancet, 2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineNew England Journal of Medicine, 2020
- Correlates of protection against SARS-CoV-2 in rhesus macaquesNature, 2020
- What are the roles of antibodies versus a durable, high quality T-cell response in protective immunity against SARS-CoV-2?Vaccine: X, 2020
- Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patientsScience Immunology, 2020
- Validation and clinical evaluation of a SARS-CoV-2 surrogate virus neutralisation test (sVNT)Emerging Microbes & Infections, 2020
- A Ready Reckoner for the Calculation of Geometric Mean Antibody TitresJournal of General Microbiology, 1958